Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
59.46B
Market cap59.46B
Price-Earnings ratio
-184.10
Price-Earnings ratio-184.10
Dividend yield
Dividend yield
Average volume
1.13M
Average volume1.13M
High today
$457.29
High today$457.29
Low today
$452.01
Low today$452.01
Open price
$452.01
Open price$452.01
Volume
212.55K
Volume212.55K
52 Week high
$469.81
52 Week high$469.81
52 Week low
$205.87
52 Week low$205.87

ALNY News

TipRanks 23h
Alnylam Pharmaceuticals’ ELEVATE Study: A Closer Look at AHP Management

Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

TipRanks 23h
Alnylam’s ALN-APP Study: A Promising Step in Alzheimer’s Treatment

Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

TipRanks 23h
Alnylam’s NeuroFeeL Study: A Potential Game-Changer for hATTR Amyloidosis

Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

Analyst ratings

76%

of 33 ratings
Buy
75.8%
Hold
21.2%
Sell
3%

More ALNY News

TipRanks 23h
Alnylam’s ConTTRibute Study: A Closer Look at Real-World Impact on ATTR Amyloidosis

Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

TipRanks 23h
Alnylam’s Patisiran-LNP Study: Key Insights for Investors

Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

Seeking Alpha 2d
Regeneron posts late-stage trial win for myasthenia gravis drug developed with Alnylam

Regeneron Pharmaceuticals (NASDAQ:REGN) announced on Tuesday that a Phase 3 trial for its RNA-based therapy cemdisiran, developed with Alnylam Pharmaceuticals (...

Regeneron posts late-stage trial win for myasthenia gravis drug developed with Alnylam

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.